However, the addition of cetuximab to standard chemotherapy failed to show any improvement in the survival of GC patients in the phase III EXPAND trial.589 This study was performed in GC patients not selected by EGFR status, which may be the reason for its failure. Here, EGFR is linked to gastric cancer.